AR085163A1 - Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos - Google Patents
Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usosInfo
- Publication number
- AR085163A1 AR085163A1 ARP120100455A ARP120100455A AR085163A1 AR 085163 A1 AR085163 A1 AR 085163A1 AR P120100455 A ARP120100455 A AR P120100455A AR P120100455 A ARP120100455 A AR P120100455A AR 085163 A1 AR085163 A1 AR 085163A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- amino
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen 4-amino-2-butenamidas que tienen actividad farmacológica, composiciones farmacéuticas que las contienen, y métodos para el tratamiento de enfermedades mediadas por la enzima catepsina C.Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: cada uno de R1 y R2 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, cicloalquenilo C5-8, bicicloalquilo C6-10 heterocicloalquilo, cicloalquil C3-8-alquilo C1-6, cicloalquenil C5-8-alquilo C1-6, heterocicloalquil-alquilo C1-6, arilo, heteroarilo, aril-alquilo C1-6 y heteroarilalquilo C1-6; donde cualquier alquilo C1-8, alquenilo C2-8 o alquinilo C2-8 está opcionalmente sustituido de una a tres veces, independientemente, por CF3, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4, -SO2N-alquil C1-4-alquilo C1-4, amino, alquil-C1-4amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo o alcoxi C1-4; y donde cualquier grupo cicloalquilo, cicloalquenilo, bicicloalquilo o heterocicloalquilo está opcionalmente sustituido de una a tres veces, independientemente, por alquilo C1-4, haloalquilo C1-4, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4 -SO2N-alquil C1-4-alquilo C1-4, amino, alquil C1-4 amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo, alcoxi C1-4, arilo o aril-alquilo C1-4, donde el resto arilo de dicho arilo o aril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; y donde cualquier grupo arilo o heteroarilo está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, alquilo C1-6, cicloalquilo C3-6, cicloalquenilo C5-6, haloalquilo C1-6, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4, -SO2N-alquil C1-4-alquilo C1-4, amino, alquil C1-4 amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo, alcoxi C1-4, alquil C1-4tio-, arilo, heteroarilo, aril-alquilo C1-4 o heteroaril-alquilo C1-4; donde cualquier resto arilo o heteroarilo de dicho arilo, heteroarilo, aril-alquilo C1-4 o heteroaril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; y donde cualquier cicloalquilo C3-6 está opcionalmente sustituido de una a tres veces, independientemente, por alquilo C1-4, arilo o heteroarilo; donde dicho arilo o heteroarilo está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; o R1 y R2, tomados junto con el nitrógeno al que están unidos, representan un anillo saturado o insaturado de 5 a 7 miembros que contiene opcionalmente otro heteroátomo que es oxígeno, nitrógeno o azufre, donde dicho anillo está opcionalmente condensado con un anillo cicloalquilo C3-8, heterocicloalquilo, arilo o heteroarilo; o R1 y R2, tomados junto con el nitrógeno al que están unidos, representan un sistema de anillos bicíclico, puenteado, de 6 a 10 miembros opcionalmente condensado con un anillo cicloalquilo C3-8, heterocicloalquilo, arilo o heteroarilo; y R3 es hidrógeno, alquilo C1-8, haloalquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-6, cicloalquenilo C5-6, cicloalquil C3-6-alquilo C1-4, cicloalquenil C5-6-alquilo C1-4 o aril-alquilo C1-4, donde el resto arilo del aril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, alquilo C1-4 ó -CF3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441840P | 2011-02-11 | 2011-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085163A1 true AR085163A1 (es) | 2013-09-11 |
Family
ID=46638952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100455A AR085163A1 (es) | 2011-02-11 | 2012-02-10 | Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos |
Country Status (23)
Country | Link |
---|---|
US (2) | US8841463B2 (es) |
EP (1) | EP2672821B9 (es) |
JP (1) | JP5931929B2 (es) |
KR (1) | KR20140048857A (es) |
CN (1) | CN103491777B (es) |
AR (1) | AR085163A1 (es) |
AU (1) | AU2012214405B2 (es) |
BR (1) | BR112013020510A2 (es) |
CA (1) | CA2827157A1 (es) |
CL (1) | CL2013002325A1 (es) |
CO (1) | CO6741219A2 (es) |
DO (1) | DOP2013000182A (es) |
EA (1) | EA023168B1 (es) |
ES (1) | ES2583091T3 (es) |
IL (1) | IL227814A0 (es) |
MA (1) | MA34961B1 (es) |
MX (1) | MX2013009279A (es) |
PE (1) | PE20140999A1 (es) |
SG (1) | SG192669A1 (es) |
TW (1) | TW201302736A (es) |
UY (1) | UY33905A (es) |
WO (1) | WO2012109415A1 (es) |
ZA (1) | ZA201306074B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
AU2002232558A1 (en) * | 2000-12-12 | 2002-06-24 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
WO2008125945A2 (en) | 2007-04-12 | 2008-10-23 | Pfizer Inc. | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c |
BRPI1015540A2 (pt) | 2009-05-07 | 2019-09-24 | Astrazeneca Ab | ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750'' |
UY32827A (es) | 2009-08-12 | 2011-02-28 | Glaxo Group Ltd | Inhibidores de catepsina c |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
-
2012
- 2012-02-09 SG SG2013060165A patent/SG192669A1/en unknown
- 2012-02-09 KR KR1020137023618A patent/KR20140048857A/ko not_active Application Discontinuation
- 2012-02-09 ES ES12744272.1T patent/ES2583091T3/es active Active
- 2012-02-09 PE PE2013001836A patent/PE20140999A1/es not_active Application Discontinuation
- 2012-02-09 BR BR112013020510A patent/BR112013020510A2/pt not_active IP Right Cessation
- 2012-02-09 UY UY0001033905A patent/UY33905A/es unknown
- 2012-02-09 WO PCT/US2012/024428 patent/WO2012109415A1/en active Application Filing
- 2012-02-09 CN CN201280017698.7A patent/CN103491777B/zh not_active Expired - Fee Related
- 2012-02-09 US US13/984,061 patent/US8841463B2/en not_active Expired - Fee Related
- 2012-02-09 AU AU2012214405A patent/AU2012214405B2/en not_active Ceased
- 2012-02-09 TW TW101104141A patent/TW201302736A/zh unknown
- 2012-02-09 MX MX2013009279A patent/MX2013009279A/es not_active Application Discontinuation
- 2012-02-09 CA CA2827157A patent/CA2827157A1/en not_active Abandoned
- 2012-02-09 EA EA201391155A patent/EA023168B1/ru not_active IP Right Cessation
- 2012-02-09 MA MA36229A patent/MA34961B1/fr unknown
- 2012-02-09 EP EP12744272.1A patent/EP2672821B9/en active Active
- 2012-02-09 JP JP2013553538A patent/JP5931929B2/ja not_active Expired - Fee Related
- 2012-02-10 AR ARP120100455A patent/AR085163A1/es unknown
-
2013
- 2013-08-05 IL IL227814A patent/IL227814A0/en unknown
- 2013-08-09 DO DO2013000182A patent/DOP2013000182A/es unknown
- 2013-08-09 CL CL2013002325A patent/CL2013002325A1/es unknown
- 2013-08-09 CO CO13190045A patent/CO6741219A2/es unknown
- 2013-08-13 ZA ZA2013/06074A patent/ZA201306074B/en unknown
-
2014
- 2014-08-21 US US14/464,734 patent/US9187461B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL227814A0 (en) | 2013-09-30 |
EP2672821B1 (en) | 2016-04-20 |
JP2014506577A (ja) | 2014-03-17 |
AU2012214405B2 (en) | 2015-07-23 |
JP5931929B2 (ja) | 2016-06-08 |
US8841463B2 (en) | 2014-09-23 |
US20130324584A1 (en) | 2013-12-05 |
BR112013020510A2 (pt) | 2016-07-12 |
AU2012214405A1 (en) | 2013-04-18 |
SG192669A1 (en) | 2013-09-30 |
MX2013009279A (es) | 2013-10-28 |
NZ614540A (en) | 2015-03-27 |
EP2672821B9 (en) | 2016-11-23 |
UY33905A (es) | 2012-08-31 |
WO2012109415A1 (en) | 2012-08-16 |
PE20140999A1 (es) | 2014-09-11 |
DOP2013000182A (es) | 2014-03-16 |
CA2827157A1 (en) | 2012-08-16 |
CO6741219A2 (es) | 2013-08-30 |
KR20140048857A (ko) | 2014-04-24 |
MA34961B1 (fr) | 2014-03-01 |
EA023168B1 (ru) | 2016-04-29 |
ZA201306074B (en) | 2014-04-30 |
ES2583091T3 (es) | 2016-09-19 |
EA201391155A1 (ru) | 2014-01-30 |
US20140364476A1 (en) | 2014-12-11 |
CN103491777A (zh) | 2014-01-01 |
EP2672821A4 (en) | 2014-08-06 |
EP2672821A1 (en) | 2013-12-18 |
TW201302736A (zh) | 2013-01-16 |
CN103491777B (zh) | 2015-05-06 |
CL2013002325A1 (es) | 2014-01-03 |
US9187461B2 (en) | 2015-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079231A1 (es) | Derivados de imidazoquinolina | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
PE20141358A1 (es) | Polimorfos de inhibidores de cinasas | |
UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
AR074966A1 (es) | Compuestos amino-heterociclicos | |
AR076707A1 (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
AR071480A1 (es) | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
UY32077A (es) | Inhibidores de quinasa tipo polo | |
CO6761373A2 (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas | |
PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
PE20141391A1 (es) | Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico | |
CO6321246A2 (es) | Compuestos novedosos activos como antagonistas de receptor muscarinico | |
AR085163A1 (es) | Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos | |
AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides | |
PE20121507A1 (es) | Derivados de (heterociclo-piperidina condensada)-(piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona como inhibidores de p75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |